Elypta raised a $21 million Series A to develop metabolism-based multi-cancer early detection.
JUN 20, 2022
Elypta provides the missing dynamic biological signal that unlocks risk testing at scale, focusing on early cancer detection through metabolism-based liquid biopsy solutions
Elypta provides the missing dynamic biological signal that unlocks risk testing at scale, focusing on early cancer detection through metabolism-based liquid biopsy solutions.